MAN2B1 and alpha-mannosidosis: Our rationale for choroid plexus-targeted gene therapy in this study was to complement enzyme replacement for alpha-mannosidosis with a single dose of rAAV vector into the CSF that will transduce and remodel choroid plexus epithelia to produce a steady supply of LAMAN for delivery throughout the brain, as occurs in other murine LSDs [43].